{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T17:36:25Z","timestamp":1793208985037,"version":"4.5.0"},"reference-count":24,"publisher":"American Society of Hematology","issue":"24","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6,11]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>The phase 3 CRISTALLO trial compared first-line fixed-duration venetoclax-obinutuzumab (VenO) vs fludarabine, cyclophosphamide, and rituximab (FCR)\/bendamustine-rituximab (BR) in patients with chronic lymphocytic leukemia (CLL), using undetectable minimal residual disease (uMRD) as the sole primary end point. Previously untreated patients with a cumulative illness rating scale score \u22646 and creatinine clearance \u226570 mL\/min without del(17p)\/TP53 mutations were randomized 1:1 to VenO or FCR\/BR. The primary end point was uMRD (&amp;lt;10\u22124) in peripheral blood (PB) using next-generation sequencing at month 15. Key secondary end points included uMRD (&amp;lt;10\u22124) in PB and bone marrow (BM) at end of treatment (EOT) and progression-free survival (PFS). uMRD at deeper cutoffs were explored. At data cutoff (19 March 2024), 80 patients received VenO, and 86 received FCR\/BR. Baseline characteristics were generally balanced across arms. The primary end point was met: 81.3% (VenO) and 54.7% (FCR\/BR) achieved uMRD (&amp;lt;10\u22124) in PB at month 15 (P = .0004). uMRD (&amp;lt;10\u22124) in PB and BM at EOT was also higher with VenO vs FCR\/BR. Short follow-up precluded evaluation of PFS at the first planned interim analysis; however, fewer patients progressed\/died with VenO vs FCR\/BR (7 vs 13). At month 15, 65.0% (VenO) and 25.6% (FCR\/BR) achieved uMRD (&amp;lt;10\u22126) in PB. The overall safety profile was consistent with the known safety profile of each drug. No patient in the VenO arm was deemed high risk for tumor lysis syndrome (TLS) after obinutuzumab debulking; no clinical TLS occurred. These results confirm and extend the findings from the GAIA-CLL13 trial, validating increased depth of response with VenO vs chemoimmunotherapies. This trial was registered at www.clinicaltrials.gov as NCT04285567.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2025030630","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T18:37:02Z","timestamp":1772476622000},"page":"2895-2904","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["Fixed-duration VenO vs FCR\/BR in fit patients with untreated CLL: primary analysis of the phase 3 CRISTALLO trial"],"prefix":"10.1182","volume":"147","author":[{"given":"Jeff P.","family":"Sharman","sequence":"first","affiliation":[{"name":"1Willamette Valley Cancer Institute, Sarah Cannon Research, Eugene, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8327-1396","authenticated-orcid":false,"given":"Luca","family":"Laurenti","sequence":"additional","affiliation":[{"name":"2Department of Diagnostic Imaging, Oncological Radiotherapy and Hematology, Agostino Gemelli University Hospital Foundation IRCCS, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Ferrant","sequence":"additional","affiliation":[{"name":"3Department of Hematology, H\u00f4pital Lyon-Sud, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8171-0674","authenticated-orcid":false,"given":"Luis Felipe","family":"Casado Montero","sequence":"additional","affiliation":[{"name":"4Hospital General Universitario de Toledo, Toledo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen P.","family":"Mulligan","sequence":"additional","affiliation":[{"name":"5Department of Haematology, Royal North Shore Hospital, Sydney, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosemary","family":"Harrup","sequence":"additional","affiliation":[{"name":"6Cancer and Blood Services, Royal Hobart Hospital and University of Tasmania, Hobart, TAS, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0308-6458","authenticated-orcid":false,"given":"Stephen","family":"Opat","sequence":"additional","affiliation":[{"name":"7Monash Health, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7363-8684","authenticated-orcid":false,"given":"Adalberto","family":"Ibatici","sequence":"additional","affiliation":[{"name":"8Division of Hematology and Bone Marrow Transplant, IRCCS Ospedale Policlinico San Martino, Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6431-6878","authenticated-orcid":false,"given":"Roberto","family":"Marasca","sequence":"additional","affiliation":[{"name":"9Department of Medical and Surgical Sciences, Section of Hematology, University of Modena and Reggio Emilia, Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Sportoletti","sequence":"additional","affiliation":[{"name":"10Department of Medicine and Surgery, Institute of Hematology, Centro di Ricerca Emato-Oncologica, University of Perugia, Perugia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Thadani-Mulero","sequence":"additional","affiliation":[{"name":"11Roche Products Ltd, Welwyn Garden City, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6169-696X","authenticated-orcid":false,"given":"Oscar","family":"Cazares","sequence":"additional","affiliation":[{"name":"12Genentech, Inc, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5903-721X","authenticated-orcid":false,"given":"Weize","family":"Huang","sequence":"additional","affiliation":[{"name":"12Genentech, Inc, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanwen","family":"Jiang","sequence":"additional","affiliation":[{"name":"12Genentech, Inc, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Clark","sequence":"additional","affiliation":[{"name":"11Roche Products Ltd, Welwyn Garden City, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun Yong","family":"Jin","sequence":"additional","affiliation":[{"name":"12Genentech, Inc, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Boyer","sequence":"additional","affiliation":[{"name":"12Genentech, Inc, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3714-9824","authenticated-orcid":false,"given":"Franck","family":"Morschhauser","sequence":"additional","affiliation":[{"name":"13Department of Hematology, Centre Hospitalier R\u00e9gional Universitaire de Lille, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"9747","key":"2026061111220055600_bib1","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"issue":"5","key":"2026061111220055600_bib2","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJMoa1817073","article-title":"Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia","volume":"381","author":"Shanafelt","year":"2019","journal-title":"N Engl J Med"},{"issue":"23","key":"2026061111220055600_bib3","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and obinutuzumab in patients with CLL and coexisting conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"N Engl J Med"},{"issue":"22","key":"2026061111220055600_bib4","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1182\/blood.2021014488","article-title":"Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort","volume":"139","author":"Tam","year":"2022","journal-title":"Blood"},{"issue":"34","key":"2026061111220055600_bib5","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1200\/JCO.21.00807","article-title":"Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: primary analysis results from the minimal residual disease cohort of the randomized phase II CAPTIVATE study","volume":"39","author":"Wierda","year":"2021","journal-title":"J Clin Oncol"},{"issue":"7","key":"2026061111220055600_bib6","doi-asserted-by":"crossref","first-page":"EVIDoa2200006","DOI":"10.1056\/EVIDoa2200006","article-title":"Fixed-duration ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities","volume":"1","author":"Kater","year":"2022","journal-title":"NEJM Evid"},{"issue":"5","key":"2026061111220055600_bib7","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1182\/blood-2018-03-839688","article-title":"Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab","volume":"133","author":"Langerak","year":"2019","journal-title":"Blood"},{"issue":"9","key":"2026061111220055600_bib8","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1200\/JCO.2011.36.9348","article-title":"Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial","volume":"30","author":"B\u00f6ttcher","year":"2012","journal-title":"J Clin Oncol"},{"issue":"22","key":"2026061111220055600_bib9","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1182\/blood.2019001077","article-title":"Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy","volume":"134","author":"Thompson","year":"2019","journal-title":"Blood"},{"issue":"24","key":"2026061111220055600_bib10","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1182\/blood-2016-05-714162","article-title":"Minimal residual disease is an independent predictor for 10-year survival in CLL","volume":"128","author":"Kwok","year":"2016","journal-title":"Blood"},{"issue":"12","key":"2026061111220055600_bib11","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1080\/10428194.2022.2098291","article-title":"Utility of measurable residual disease for predicting treatment outcomes with BCR- and BCL2-targeted therapies in patients with CLL","volume":"63","author":"Wierda","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2026061111220055600_bib12","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1038\/s41467-023-37648-w","article-title":"Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia","volume":"14","author":"Al-Sawaf","year":"2023","journal-title":"Nat Commun"},{"issue":"2","key":"2026061111220055600_bib13","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1182\/blood-2015-06-651125","article-title":"Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial","volume":"127","author":"Fischer","year":"2016","journal-title":"Blood"},{"issue":"7","key":"2026061111220055600_bib14","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(16)30051-1","article-title":"First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial","volume":"17","author":"Eichhorst","year":"2016","journal-title":"Lancet Oncol"},{"issue":"12","key":"2026061111220055600_bib15","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions","volume":"370","author":"Goede","year":"2014","journal-title":"N Engl J Med"},{"issue":"9","key":"2026061111220055600_bib16","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1182\/blood-2017-06-792333","article-title":"A model for predicting effect of treatment on progression-free survival using MRD as a surrogate end point in CLL","volume":"131","author":"Dimier","year":"2018","journal-title":"Blood"},{"issue":"19","key":"2026061111220055600_bib17","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1056\/NEJMoa2213093","article-title":"First-line venetoclax combinations in chronic lymphocytic leukemia","volume":"388","author":"Eichhorst","year":"2023","journal-title":"N Engl J Med"},{"issue":"25","key":"2026061111220055600_bib18","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"issue":"8","key":"2026061111220055600_bib19","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1056\/NEJMoa2409804","article-title":"Fixed-duration acalabrutinib combinations in untreated chronic lymphocytic leukemia","volume":"392","author":"Brown","year":"2025","journal-title":"N Engl J Med"},{"issue":"9","key":"2026061111220055600_bib20","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/S1470-2045(20)30443-5","article-title":"Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial","volume":"21","author":"Al-Sawaf","year":"2020","journal-title":"Lancet Oncol"},{"issue":"4","key":"2026061111220055600_bib21","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa2310063","article-title":"Chronic lymphocytic leukemia therapy guided by measurable residual disease","volume":"390","author":"Munir","year":"2024","journal-title":"N Engl J Med"},{"issue":"11","key":"2026061111220055600_bib22","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1056\/NEJMoa2515458","article-title":"Fixed-duration versus continuous treatment for chronic lymphocytic leukemia","volume":"394","author":"Al-Sawaf","year":"2026","journal-title":"N Engl J Med"},{"issue":"S1","key":"2026061111220055600_bib23","first-page":"211","article-title":"The triple combination of venetoclax-ibrutinib-obinutuzumab prolongs progression-free survival compared to venetoclax-CD20-antibody combinations and chemoimmunotherapy in treatment-naive chronic lymphocytic leukemia: final analysis from the phase 3 GAIA\/CLL13 trial","volume":"9","author":"F\u00fcrstenau","year":"2025","journal-title":"Hemasphere"},{"issue":"2","key":"2026061111220055600_bib24","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/s41375-019-0554-1","article-title":"Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study","volume":"34","author":"Bosch","year":"2020","journal-title":"Leukemia"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/24\/2895\/2525726\/blood_bld-2025-030630-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/24\/2895\/2525726\/blood_bld-2025-030630-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T15:22:10Z","timestamp":1781191330000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/147\/24\/2895\/566888\/Fixed-duration-VenO-vs-FCR-BR-in-fit-patients-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,11]]},"references-count":24,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2026,6,11]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2025030630","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6,11]]},"published":{"date-parts":[[2026,6,11]]}}}